Purpose: Osteosarcoma is the most common malignancy of the bone in children and adolescents. There is an urgent need for the development of novel drugs to treat it. Nudol (1), a phenanthrene compound from the traditional Chinese medicine, Dendrobium nobile, exhibited antiproliferative activity against osteosarcoma cells. Therefore, the aim of the present study was to investigate the role and underlying mechanism of nudol(1) as potential chemotherapy for osteosarcoma. Methods: Cell viability was determined by MTT assay. Cell-cycle phase distribution was analyzed by flow cytometry and Western blot. DAPI staining was used for morphology observation. Apoptosis was analysis via flow cytometry. The expression levels of mRNA and protein related to capase-mediated apoptotic pathway were detected by real-time PCR and western blotting. Migration was determined by wound healing assays. Results: Nudol(1) significantly decreased cell viability in several cancer cell lines. Moreover, nudol(1) caused cell cycle arrest at G2/M phase in U2OS cells, and it also induced cell apoptosis through the caspase-dependent pathway. In addition, treatment with nudol(1) suppressed the migration of U2OS cells. Conclusion: The present study, for the first time, demonstrated effects of nudol(1) on OS in vitro and the potential molecular mechanisms. Accordingly, nudol(1) might have the potential for further development as a lead compound against bone tumor.
Introduction
Osteosarcoma is the most common malignant bone tumor, particularly in children, adolescents, and young adults. 1 Pathologically, osteosarcoma is derived from mesenchymal cells which are characterized by spindle cells and aberrant osteoid formation. The primary sites of osteosarcoma are typically located at the proximal tibia, the distal femur, and the distal humerus, with about 60% lesions arising from the knee. 2 Traditional therapeutic approaches for osteosarcoma include local control of the primary lesion by surgery and/or chemotherapy, and treatment of disseminated disease with multi-agent cytotoxic chemotherapy. 3 However, the current five-year survival rate for patients with osteosarcoma is only 5%-20%, 4 and a significant proportion of osteosarcoma cases has shown strong resistance to the present chemotherapies. Consequently, development of new, more effective, and well-tolerated therapeutics remains a pressing task.
Medicinal plants are important sources of novel therapeutic drugs for the treatment of osteosarcoma. 5 Many species of the genus Dendrobium Sw. (family Orchidaceae) have been used for over 1,000 years as firstrate herbs in traditional Chinese medicine (TCM). 6 A number of bioactive constituents from Dendrobium plants, such as polysaccharides, 7 bibenzyls, 8 phenanthrenes, 9 and alkaloids 10 were obtained and displayed diverse pharmacological effects including anticancer, anti-diabetic, neuroprotective, and immunomodulating activities. The most noteworthy constituent is erianin, which is a natural bibenzyl compound derived from Dendrobium chrysotoxum Lindl and has been used as an analgesic in TCM. 11 Previous studies have proved the antitumor activity of erianin against a panel of human cancer cell lines, including breast cancer T47D, 12 promyelocytic leukemia HL-60, 13 patocarcinoma Bel7402 and melanoma A375, 14 and osteosarcoma cells. 15 Structurally similar to erianin, some phenanthrene derivatives were also found to display potent antitumor activity. [16] [17] [18] [19] The latest study demonstrated that chrysotoxene induced the apoptosis of HepG2 cells in vitro and in vivo via activation of the mitochondria-mediated apoptotic signaling pathway. 20 During the course of our search for bioactive natural products from Dendrobium nobile Lindl., five phenanthrene derivatives were isolated and structurally characterized as nudol(1), 21 confusarin (2), 22 3,7-dihydroxy-2,4-dimethoxy-9,10-dihydrophenanthrene (3), 23 3,7-dihydroxy-2,4-dimethoxyphenanthrene (4), 24 and 3,7-dihydroxy-2,4,8-trimethoxyphenanthrene (5) 25 (Figure 1 ) (Figures S4-S13). Among them, nudol(1) was initially isolated from the orchids Eulophia nuda Linda, Eria carinata Gibson, and Eria stricta Lindl, 21 and significantly inhibited the growth of HeLa cells (IC 50 =20.18 μM). 26 A preliminary screening of the anti-proliferative activity of 1-5 against osteosarcoma cells MG63 and U2OS revealed that nudol(1) exerted remarkable growth inhibitory effect ( Figure 2 ). Therefore, the aim of the present work was to perform an antitumor evaluation of nudol(1) toward the osteosarcoma cells and to investigate the critical factors for the cell growth inhibition including cell cycle, apoptosis, and migration.
Materials and methods
General experimental procedures NMR spectra were acquired on a Bruker Avance DRX600 NMR spectrometer (Bruker BioSpin AG) with residual solvent peaks as references (CDCl 3 : δ H 7.26, δ C 77.0). Semipreparative HPLC separations were carried out on an Agilent 1260 series (Agilent Technologies Inc.) using an Agilent Zorbax SB-C 18 column (250×9.4 mm, 5 μm). ESIMS analyses were carried out on an Agilent 1,260-6,460 Triple Quad LC-MS instrument (Agilent Technologies Inc.). Column chromatography (CC) was performed on Silica gel (200-300 mesh, Yantai Jiangyou Silica Gel Development Co.), reversed phase (RP) C18 silica gel (Merck) and Sephadex LH-20 gel (GE Healthcare Bio-Sciences). All solvents used for CC were of analytical grade (Tianjin Fuyu Fine Chemical Co. Ltd.), and solvents used for HPLC were of HPLC grade (Oceanpak Alexative Chemical Ltd.).
Plant material
The stems of Dendrobium nobile were purchased in April 2015 from Huoshan, Anhui Province, and were authenticated by Dr. Jinchuan Zhou from School of Pharmacy, Linyi University. A voucher specimen (No. DN20150420) has been preserved at School of Biological Science and Technology, University of Jinan.
Extraction and isolation
The air-dried and powdered stems (2.5 kg) of D. nobile were extracted with 95% EtOH (3×10 L, each for 5 days) (DOX, Sigma Chemical Co, purity >98%) was dissolved in distilled water and used as a positive control.
Cell viability assay
The cells were cultured in 96-well plates, and each well was seeded with 1×10 4 cells. The viability of cells was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, 10 μL of MTT (5 mg/mL in PBS) was added to each well, and the plates were incubated for 4 hrs at 37°C. In this step, 100 μL of DMSO was added to dissolve the formazan crystals. The optical density was measured at an absorbance wavelength of 490 nm using a Microplate Reader (Tecan). The survival rate was calculated according to the following formula: Survival rate = absorbance of treatment/absorbance of control ×100%.
DNA fragmentation analysis with DAPI staining
Cells (1×10 5 cells/well) were seeded in six-well plates. After attachment, cells were treated with various concentrations of nudol(1) for 48 hrs. The cells were then fixed with 4% polyoxymethylene (PFA, Sigma-Aldrich) for 30 mins, washed twice with PBS, and incubated with 10 μg/ mL DAPI (4,6-diamidino-2-phenylindole, Sigma-Aldrich) for 10 mins at room temperature in the dark. After washing with PBS two times, the images were photographed by an inverted fluorescence microscope (Leica).
Apoptosis analysis by flow cytometry
Cell apoptosis assays were performed with an Annexin V-FITC apoptosis detection kit (BD Biosciences) according to the manufacturer's protocol. OS cells were treated with different doses of nudol(1) for 48 hrs. Cells were washed twice with PBS and harvested by re-suspension in 100 μL of 1× binding buffer, followed by incubation with 5 μL each of Annexin V fluorescein isothiocyanate and propidium iodide for 15 mins at room temperature in the dark. Finally, adding 400 μL of 1× binding buffer to the tube and cell apoptosis was measured by flow cytometer (Becton-Dickinson). The data were analyzed using Flowjo 7.0.
Cell cycle analysis by flow cytometry
Cells were incubated with the indicated concentrations of nudol(1) for 48 hrs. After incubation, cells were collected, washed twice with PBS, and then fixed in cold 70% ethanol overnight at 4°C. The cells were then again washed in PBS once and suspended in a staining buffer (10 μg/mL propidium iodide, 0.5% Tween 20, 0.1% RNase in PBS) for 30 mins at room temperature. Cell cycle analysis was performed on the flow cytometer (Becton-Dickinson).
Migration determination
Cell migration was determined by wound-healing assay. The cells were seeded at a density of 5×10 5 cells/well in six-well plates. After the cell monolayer was formed, a micropipette tip was used to create wounds. The cells were then washed with PBS and replaced by serum-free DMEM-high glucose medium containing various concentrations of nudol (1) . The cell migration progress into the wound area was photographed using an inverted microscope at 0, 6, 18, and 24 hrs. The average wound size represented the relative cell migration.
Reverse transcription and quantitative real-time PCR
Total RNA of U2OS cells treated with or without nudol(1) for 48 hrs was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. The quantity of RNA was determined using the ultramicro spectrophotometer (NanoDrop 2,000, Thermo Fisher Scientific). Complementary DNA was generated in a 20 μL reaction with 1 µg of total RNA using a RT reaction kit (Promega) according to the manufacturer's instruction. Real-time PCR was performed using a CRX Connect Real-Time system (Bio-Rad) and using SYBR Premix Ex Taq™ (TaKaRa) as a DNA-specific fluorescent dye. Real-time PCR was carried out for 40 cycles at 95°C for 10 s and 60°C for 30 s. Gene expression levels were calculated relative to the housekeeping β-actin, and all the reactions were repeated at least three times. Primer sequences for detection of mRNA expression were synthesized as shown in Table 1 .
Western blot analysis
The U2OS cells were treated with the different doses of nudol(1) for 48 hrs. The cells were then washed twice with PBS solution, and total proteins were extracted from cells using 1× RIPA buffer containing protease/phosphatase inhibitor (Beyotime Institute of Biotechnology, Jiangsu, China). The U2OS cells were prepared using a ProteoJET cytoplasmic protein extraction kit (Fermentas; Thermo Fisher Scientific, Inc.). Protein concentrations were determined using BCA protein assay kit (Beyotime Institute of Biotechnology, Jiangsu, China). Equivalent quantities of protein were electrophoretically separated on a 10% sodium dodecyl sulfate-polyacrylamide gel. The total protein were then transferred onto polyvinylidene fluoride membranes and blocked for 60 mins with 3% bovine serum albumin solution prepared in PBS at room temperature. A 1:1,000 dilution of the primary antibodies (Bax, Bcl-2, caspase-3, caspase-9, caspase-8, CDK1, cyclinE1, cyclinD1, cyclinB1, p21, p-Rb, cytochrome c, and β-actin) were incubated overnight at 4°C. The membranes were washed three times with TBST buffer (0.05% Tris-buffered saline and Tween 20). The appropriate peroxidase-conjugated secondary antibody (dilution of 1:5,000) was incubated for 2 hrs at room temperature. Subsequently, the results were visualized with enhanced chemiluminescence reagent (Merck Millipore) using imaging system (Chemi-Doc XRS imager, Bio-Rad).
Statistical analysis
All experimental values were expressed as mean ± standard deviation (SD) of at least three independent experiments. SPSS 18.0 statistical software package (SPSS Inc) was used to perform all statistical analysis. The statistical significance of the differences between groups was evaluated by Student's t-test. P<0.05 was considered to indicate a statistically significant difference. *p<0.05, **p<0.01, and ***p<0.001, respectively.
Results

Nudol(1) decreased the cell viability of osteosarcoma cells
Compounds 1-5 were initially evaluated for their antiproliferative activity against the human osteosarcoma cell lines U2OS and MG63 at 20 μM, using MTT assay. The results were shown in Figure 2A and B, and nudol(1) exhibited obvious anti-proliferative activity against both cells. To further investigate the effect of nudol(1) on cell proliferation, MG63 and U2OS cells were treated by various concentrations of nudol(1) for 24, 48, and 72 hrs. We found that nudol(1) decreased osteosarcoma cell viability in dose-and time-dependent manners ( Figure 2C and D Figure 2E ). These results demonstrated that U2OS cells showed the lowest IC 50 value among the cancer cell lines tested. Therefore, we further examined the effect of nudol(1) on the U2OS cells. 
Nudol(1) induced cell cycle arrest at G2/M phase in OS cells
To verify how treatment of nudol(1) caused the inhibition of U2OS cell proliferation, cell-cycle distribution was analyzed by flow cytometry (Figure 3A and B) . Nudol(1) increased the cell number at G2/M phase after 48 hrs treatment with different concentrations, while the percentage of cells in G1 phase decreased significantly. The results indicated that nudol(1) effectively arrested the cell cycle at G2/M phase compared to the control group. In addition, we explored the effects of nudol(1) on cell cycle in MG63 cells. Results further confirmed that nudol(1) caused cell cycle arrests at G2/M phase ( Figure S1 ).
To study the molecular mechanisms of how nudol(1) induced G2/M phase arrest, the cell cycle arrest-related cyclin-dependent kinases (CDK) family transcriptional level was examined using the real-time PCR. The results displayed that treatment of nudol(1) prominently decreased the transcription of CDK1, CDK2, CDK4, and CDK10 compared to the control group ( Figure 3C ). Furthermore, the expression of cell cycle-related proteins in response to treatment of nudol(1) was measured by Western blotting. The expression of Cyclin B1 and p21 (DNA synthesis inhibitor) was up-regulated, and the level of CDK1 and p-Rb was down-regulated ( Figure 3D ). All these observations demonstrated that nudol(1) triggered G2/M phase arrest by regulating cell cycle-related proteins.
Nudol(1) induced apoptosis of OS cells
We next investigated whether the reduction of cell viability by nudol(1) treatment was due to the induction of apoptosis, and DAPI staining assay was thus carried out. Treatment of nudol(1) for 48 hrs increased the number of hallmarks of U2OS cell apoptosis in a concentrationdependent manner, including pyknosis (shrinkage) and condensed chromatin (brighter nuclei) ( Figure 4A ). We then analyzed U2OS cell lineby flow cytometry after staining with Annexin V-FITC and propidium iodide ( Figure 4B ). Similar results showed ( Figure 4C ) that treatment with nudol(1) increased the percentage of apoptotic cells from 2.58±0.50% (control) to 11.59±0.29% (20 μM). Furthermore, flow cytometric analysis via Annexin V-FITC/PI was performed on MG63 cell. We also found that an increase of the number of apoptotic cells was observed in cells after exposed to nudol(1) in a dosedependent manner ( Figure S2) . These results were consistent with the cell viability assay, suggesting that higher cell growth inhibition resulting from nudol(1) could be, at least partly, due to the induction of more apoptosis in U2OS cells.
Nudol(1) induced cell apoptosis through caspase pathway
In an attempt to clarify the detailed molecular mechanism involved in apoptosis induction, we proceeded to assess the expression levels of caspase-3, 8, and 9, and modulation of the status of other apoptosis-related genes. The mRNA levels of caspase-3, 8, and 9 in the application of 20 μM nudol(1) were much higher than the control ( Figure 5A ). Furthermore, release of cytochrome c into cytosol is a key step in apoptotic process, as shown in Figure 5A and C, the mRNA and protein of cytochrome c was obviously increased in the experimental group. Subsequently, the effect of nudol(1)-treament on caspase-3, 8, and 9 activities in U2OS cells was investigated ( Figure 5B ). Western blotting revealed that nudol(1) significantly induced the cleaved forms of caspase-3, 8, and 9 of U2OS cells at 48 hrs, illustrating the activation of both extrinsic and intrinsic apoptosis pathways. Further experiments were done to examine the key players in apoptosis pathway such as Bax and Bcl-2. As shown in Figure 5D and E, the level of anti-apoptotic Bcl-2 was down-regulated, which was accompanied by an increased level of pro-apoptotic Bax in response to treatment with nudol(1). These results provided insight into the molecular mechanism of how compound nudol(1) exerted its growth inhibitory effects on osteosarcoma cells. 
Nudol(1) inhibited the mobility of OS cells
We further examined whether nudol(1) played a role in the migration of osteosarcoma cells, and wound-healing assay was then performed. The results showed that nudol(1) could effectively prevent U2OS cells from entering the wounded area ( Figure 6A and B) , and the cells treated with nudol(1) for 24 hrs demonstrated better effect than control, indicating that nudol(1) was able to efficiently inhibit cell migration. Meanwhile, wound-healing assays were used to evaluate the migration of MG63 cells that were treated with different dosages of nudol(1). The results showed that nudol(1) could also suppress migration of MG63 cells effectively ( Figure S3 ). In addition, we analyzed the effects of nudol(1) on the expression of genes involved in U2OS cell migration. The data indicated that the expression of MMP2 and MMP9 decreased significantly in the treated group. On the contrary, the expression of genes that suppress migration, such as TIMP1 and TIMP2, increased dramatically ( Figure 6C ).
Discussion
Osteosarcoma is an aggressive cancer in the skeletal system mostly diagnosed in juveniles. The high mortality rate associated with osteosarcoma indicates that the current available treatments, such as surgical resection and chemotherapy 27 are far from satisfying. Therefore, it is necessary to develop new therapeutic agents to treat osteosarcoma effectively. 28 In this study, five phenanthrene derivatives (1) (2) (3) (4) (5) were obtained from a traditional Chinese herb D. nobile, and their growth inhibitory activities against MG63 and U2OS cell lines were investigated by MTT assay. The results indicated that treatment of nudol(1) could significantly decrease the cell viability compared to the control group at 24, 48, and 72 hrs, respectively. In addition, the viability effect of nudol (1) in other cells such as MDA-MB-231, MCF-7, and A549 cells was also confirmed by MTT assay. These results demonstrated that the U2OS cells were more sensitive to nudol(1) treatment, whereas other cell lines exhibited less response. Our present work demonstrated that nudol(1) inhibited human osteosarcoma cells growth by at least partially cell cycle arrest, apoptosis induction, and migration inhibition. We firstly found that treatment of nudol(1) inhibited the viability of U2OS cells by enhancing the cell cycle arrest in the G2/M phase. As CDKs play a key role in the controlling of cell proliferation through maintaining of cell cycling, 29 we then examined the expression of several major CDKs and identified nudol(1) as a good suppressor of them. To further illustrate the mechanism, p21 which is a critical regulator of cell cycle was detected. 30 As we predicted, the expression of p21 was obviously increased upon treatment of nudol (1) , which was further confirmed by examination of the cell cyclerelated proteins CDK1/cyclin B1. In addition, the retinoblastoma tumor suppressor protein (Rb) might contribute to regulating multiple critical cellular activities in preventing tumor, including the cell cycle arrest. 31, 32 Therefore, the phosphorylation level of Rb (p-Rb) was also tested in nudol(1)-treated U2OS cells and was demonstrated to decrease significantly.
Apoptosis serves as a pivotal role in tumor formation and treatment response. 33 We found that nudol(1) induced apoptosis of U2OS cells in a dose-dependent way, as evidenced by flow cytometry analysis and DAPI staining. Apoptosis is a tightly regulated process under the control of several signaling pathways such as the caspase pathway. 34 Activation of caspase-3 plays a central role in the initiation of apoptosis, which requires the activation of initiator caspase-8 or 9. 35 From our acquired data, the exposure of U2OS cells to nudol (1) caused the cleavage and activation of caspase-3, 8 and 9 in a dose-response manner. On the other hand, apoptotic stimuli may promote the release of cytochrome c from the mitochondria to the cytoplasm, which could be inhibited by anti-apoptotic protein Bcl-2. 36 Meanwhile, pro-apoptotic protein Bax is able to decrease the inhibitory effect of Bcl-2 on the release of cytochrome c. 37, 38 The release of cytochrome c, in turn, results in the cleavage of pro-caspase-9. Activation of caspase-9 can then go on to activate caspase-3, which triggers apoptosis. 39 Our results showed that nudol(1) significantly enhanced the expression of cytochrome c and Bax while reduced Bcl-2 in U2OS cells. Thus, these results demonstrated that the caspase-dependent pathway plays a pivotal role in the apoptosis induced by nudol (1) . Moreover, we found that the migration of U2OS cells was greatly inhibited by treatment of nudol (1) . It is well known that cancer invasion and metastasis are a complicated multistep process involving numerous effects or molecules. The degradation of the extracellular matrix is an essential step in cancer invasion and metastasis. 40 Matrix metalloproteinases had been verified to degrade almost all extracellular matrix components. 41 Therefore, the homeostatic expression of MPP and their inhibitors TIMP was detected in nudol(1)treated U2OS cells. Our data demonstrated that nudol(1) could suppress the mRNA level of MMP-2 and MMP-9, and on the contrary, promote the expression of TIMP1 and TIMP2 that suppress migration, which revealed an interesting mechanism on how nudol(1) inhibited cell migration.
In summary, nudol(1) is a natural phenanthrene derivative from the Chinese herb D. nobile, the effects and potential molecular mechanisms of nudol(1) were investigated for the first time in human osteosarcoma cells. Our data showed that compound nudol(1) was able to significantly inhibit cell growth, cause G2/M cell cycle arrest, induce cell apoptosis and suppress migration of OS cells. Taken together, the current work identified nudol(1) as a potential lead compound for the development of future osteosarcoma chemotherapies.
